Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is to study the efficacy and safety of the triplet combination of TLK286, carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Telik
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Paclitaxel

Criteria

Inclusion Criteria:

• 18 years of age or older

• Histologically confirmed non-small cell lung cancer (NSCLC)

• Stage IV or IIIB (disease that is not eligible for combined modality chemotherapy and radiation)

• Measurable disease by RECIST

• ECOG status of 0-1

• Adequate liver and renal function

• Adequate bone marrow reserves

Exclusion Criteria:

• Prior chemotherapy, immunotherapy or biologic therapy for metastatic NSCLC

• Up to one prior adjuvant or neoadjuvant chemotherapy is allowed

• History of bone marrow transplantation or stem cell support

• Pregnant or lactating women